ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 67074" data-attributes="member: 3"><p><strong>The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic review and meta-analysis of randomized controlled trials</strong></p><p></p><p>Summary</p><p></p><p>Objectives</p><p></p><p>Dyslipidaemia is common in patients with subclinical hypothyroidism (SCH). To date, there is no universal agreement regarding the lipid-lowering effect of substitution treatment with L-T4 in patients with SCH. We aimed to clarify the effect by conducting this systematic review and meta-analysis of randomized controlled trials (RCTs).</p><p>Design</p><p></p><p>We systematically searched PubMed, the Cochrane Library, ClinicalTrials. gov and EMBASE for RCTs comparing substitution treatment to placebo treatment or observation. We focused on the primary outcomes of changes from baseline of total, low-density lipoprotein, and high-density lipoprotein cholesterol (TC, LDL-C and HLD-C) and triglycerides. Subgroup analyses were performed, assessing the effect of treatment duration, disease severity, and ethnicity on the occurrence of discrepancy</p><p>Results</p><p></p><p>Twelve trials, with 940 participants, were eligible for analysis. Compared with the control group, levothyroxine substitution yielded a mean reduction in TC (-0.29mmol/l, [-0.42 to -0.16]) and LDL-C (-0.22mmol/l, [-0.36 to -0.09]), with no significant effects on HDL-C (-0.04mmol/l, [-0.08 to 0.01]) or triglycerides (-0.04mmol/l, [-0.08 to 0.00]). Trials in which only patients with mild SCH (thyrotropin <10 mIU/L) were enrolled showed equivalent effects. The lowering effects were weaker, but still significant, in long-term treatment (>6 months) compared with short-term treatment (&#8804;6 months) for TC (-0.19mmol/l [-0.35, -0.03] vs. -0.50mmol/l [-0.68, -0.31], p = 0.047) and LDL-C (-0.09mmol/l [-0.16, -0.02] vs. -0.46mmol/l [-0.68, -0.25], p = 0.006).</p><p>Conclusions</p><p></p><p>Levothyroxine treatment has clear benefits on TC and LDL-C in SCH patients, including those with mild SCH.</p><p></p><p><a href="http://onlinelibrary.wiley.com/doi/10.1111/cen.13338/abstract" target="_blank">http://onlinelibrary.wiley.com/doi/10.1111/cen.13338/abstract</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 67074, member: 3"] [b]The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic review and meta-analysis of randomized controlled trials[/b] Summary Objectives Dyslipidaemia is common in patients with subclinical hypothyroidism (SCH). To date, there is no universal agreement regarding the lipid-lowering effect of substitution treatment with L-T4 in patients with SCH. We aimed to clarify the effect by conducting this systematic review and meta-analysis of randomized controlled trials (RCTs). Design We systematically searched PubMed, the Cochrane Library, ClinicalTrials. gov and EMBASE for RCTs comparing substitution treatment to placebo treatment or observation. We focused on the primary outcomes of changes from baseline of total, low-density lipoprotein, and high-density lipoprotein cholesterol (TC, LDL-C and HLD-C) and triglycerides. Subgroup analyses were performed, assessing the effect of treatment duration, disease severity, and ethnicity on the occurrence of discrepancy Results Twelve trials, with 940 participants, were eligible for analysis. Compared with the control group, levothyroxine substitution yielded a mean reduction in TC (-0.29mmol/l, [-0.42 to -0.16]) and LDL-C (-0.22mmol/l, [-0.36 to -0.09]), with no significant effects on HDL-C (-0.04mmol/l, [-0.08 to 0.01]) or triglycerides (-0.04mmol/l, [-0.08 to 0.00]). Trials in which only patients with mild SCH (thyrotropin <10 mIU/L) were enrolled showed equivalent effects. The lowering effects were weaker, but still significant, in long-term treatment (>6 months) compared with short-term treatment (≤6 months) for TC (-0.19mmol/l [-0.35, -0.03] vs. -0.50mmol/l [-0.68, -0.31], p = 0.047) and LDL-C (-0.09mmol/l [-0.16, -0.02] vs. -0.46mmol/l [-0.68, -0.25], p = 0.006). Conclusions Levothyroxine treatment has clear benefits on TC and LDL-C in SCH patients, including those with mild SCH. [url]http://onlinelibrary.wiley.com/doi/10.1111/cen.13338/abstract[/url] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top